跳到正文
原文
Medical Xpress·· 17 天前AI 评分61

ASN研究报告:SGLT2抑制剂与80岁以上慢性肾病患者死亡风险下降相关

ASN: Elderly with chronic kidney disease benefit from SGLT2 inhibitors

AI 导读

一项提交至美国肾脏病学会(ASN)肾脏周会议的真实世界研究显示,80岁及以上慢性肾病患者使用SGLT2抑制剂与两年随访死亡风险下降相关(校正HR 0.734),主要不良心血管和肾脏事件风险亦较低(aHR 0.884、0.775)。研究基于TriNetX数据库23765名倾向评分匹配患者,合著者指出该人群需要个体化风险收益评估和密切临床监测。

正文
kidney
Credit: Unsplash/CC0 Public Domain

Sodium-glucose cotransporter 2 (SGLT2) inhibitors show significant benefits for adults aged 80 years and older with chronic kidney disease (CKD), according to a study presented at Kidney Week, the annual meeting of the American Society of Nephrology, held from Oct. 21 to 25 in Denver.

Julian Doricic, M.D., from Medizinische Hochschule Hannover in Germany, and colleagues examined effects of SGLT2 inhibitor therapy in elderly adults with CKD. The analysis included 23,765 SGLT2 inhibitor users and nonusers (aged 80 years and older) who were propensity score-matched for comorbidities, laboratory parameters and frailty-associated factors, identified from the TriNetX database.

The researchers found that after two years of follow-up, there was a significant reduction in mortality among patients treated with SGLT2 inhibitors (adjusted hazard ratio [aHR], 0.734). A similar mortality benefit was seen across all predefined subgroups. SGLT2 inhibitor users also experienced benefits in terms of lower risk of both major adverse cardiovascular events (aHR, 0.884) and major adverse kidney events (aHR, 0.775).

"Very elderly individuals are historically underrepresented in or systematically excluded from large-scale randomized controlled trials due to multimorbidity and frailty. By leveraging real-world data, our research addresses a crucial blind spot in current medical literature," co-author Bernhard M.W. Schmidt, M.D., from Hannover Medical School in Germany, said in a statement. "These patients require a careful, individualized risk-benefit assessment and close clinical monitoring."

Who's behind this story?

Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

© 2026 HealthDay. All rights reserved.

Citation: ASN: Elderly with chronic kidney disease benefit from SGLT2 inhibitors (2026, November 2) retrieved 2 November 2026 from https://medicalxpress.com/news/2026-11-asn-elderly-chronic-kidney-disease.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com